Biocytogen, Qilu Pharmaceutical sign agreement for VHH antibody molecule

Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule. The deal includes an upfront payment to Biocytogen, along with eligibility for milestone payments tied to specified objectives. The licensed VHH antibody molecule originates from RenNano, Biocytogen’s technology designed to identify fully human VHH antibodies. Credit: Anamaria Mejia / Shutterstock.com. China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule. The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D)…

Source: Pharmaceutical Technology